CompletedEUCTR 2004-000751-42

A 26-week, International, Multicenter, Open-label Phase IIIb Study of the Safety and Tolerability of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in Daily Doses of 400 mg to 800 mg in ...

This historical record does not confirm current site availability.

Historical research recordGermanySchizophrenia

The study in practice

Understand this study

What did researchers investigate?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Listed locations: Germany
Study phase: Phase 3

Study clarity

Study information

Study start dateNot clearly listed

Recruitment status: Completed
Enrollment listed in the registry: 100
Sponsor: AstraZeneca AB
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: Germany
Age range: Not clearly listed
Official registry ID: EUCTR 2004-000751-42
Official title: Show the full official title
A 26-week, International, Multicenter, Open-label Phase IIIb Study of the Safety and Tolerability of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in Daily Doses of 400 mg to 800 mg in ...

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Germany

Registry details

Historical country statuses

Germany — Completed

FAQ

Questions about this study

Who is behind this study?

The study sponsor is AstraZeneca AB.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me